Compare
LENZ Therapeutics, Inc. vs Alector, Inc. vs Pelthos Therapeutics Inc. vs Relay Therapeutics, Inc.
| Latest fiscal year | LENZ Therapeutics, Inc. LENZ | Alector, Inc. ALEC | Pelthos Therapeutics Inc. PTHS | Relay Therapeutics, Inc. RLAY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $19.09M | $21.05M | $16.80M | $15.36M |
| Revenue growth (YoY) | n/a | -79.1% | n/a | +53.4% |
| Gross margin | n/a | n/a | 76.3% (computed) | n/a |
| Operating margin | -477.5% | -741.3% | -193.1% | n/m |
| Net margin | -430.3% | -679.2% | -257.9% | n/m |
| Net income | -$82.13M | -$142.93M | -$43.32M | -$276.48M |
| EPS (Diluted) | -$2.85 | -$1.39 | -$23.04 | -$1.61 |
| Operating cash flow | -$69.17M | -$184.03M | -$22.59M | -$235.46M |
| Free cash flow | -$70.00M | -$184.07M | -$22.69M | -$235.87M |
| Cash & equivalents | $25.18M | $65.80M | $17.97M | $84.02M |
| Total assets | $305.88M | $293.24M | $130.40M | $621.33M |
| Total liabilities | $21.54M | $262.59M | $91.52M | $54.27M |
| Shareholders' equity | $284.34M | $30.65M | $38.88M | $567.06M |
| Return on year-end equity | -28.9% | -466.3% | -111.4% | -48.8% |
| Shares outstanding | 31.34M | 110.36M | 3.23M | 173.87M |
Revenue, most recent five fiscal years
| Fiscal year | LENZ Therapeutics, Inc. | Alector, Inc. | Pelthos Therapeutics Inc. | Relay Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $19.09M Ended 2025-12-31 | $21.05M Ended 2025-12-31 | $16.80M Ended 2025-12-31 | $15.36M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $100.56M Ended 2024-12-31 | $0 Ended 2024-12-31 | $10.01M Ended 2024-12-31 |
| 2 years earlier | n/a | $97.06M Ended 2023-12-31 | n/a | $25.55M Ended 2023-12-31 |
| 3 years earlier | n/a | $133.62M Ended 2022-12-31 | n/a | $1.38M Ended 2022-12-31 |
| 4 years earlier | n/a | $207.09M Ended 2021-12-31 | n/a | $3.03M Ended 2021-12-31 |